blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2590647

EP2590647 - PRO-NEUROGENIC COMPOUNDS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.09.2018
Database last updated on 04.06.2024
FormerThe patent has been granted
Status updated on  06.10.2017
FormerGrant of patent is intended
Status updated on  16.05.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Board of Regents of the University of Texas System
201 West 7th Street
Austin, TX 78701 / US
[2013/20]
Inventor(s)01 / MCKNIGHT, Steven L.
5323 Harry Hines Boulevard
Dallas Texas 75390 / US
02 / PIEPER, Andrew A.
5720 Meadowhaven Drive
Plano Texas 75093 / US
03 / READY, Joseph M.
3157 Riverside Drive
Carrollton Texas 75007 / US
04 / DE BRABANDER, Jef K.
4100 Post Oak Road
Flower Mound Texas 75022 / US
 [2013/20]
Representative(s)Sutcliffe, Nicholas Robert, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
[2017/45]
Former [2013/20]Sutcliffe, Nicholas Robert, et al
Mewburn Ellis LLP 33 Gutter Lane London
EC2V 8AS / GB
Application number, filing date11804335.507.07.2011
[2017/45]
WO2011US43185
Priority number, dateUS20111317798107.07.2011         Original published format: US201113177981
US2010083205607.07.2010         Original published format: US 832056
[2013/20]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2012006419
Date:12.01.2012
Language:EN
[2012/02]
Type: A2 Application without search report 
No.:EP2590647
Date:15.05.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 12.01.2012 takes the place of the publication of the European patent application.
[2013/20]
Type: B1 Patent specification 
No.:EP2590647
Date:08.11.2017
Language:EN
[2017/45]
Search report(s)International search report - published on:US01.08.2013
(Supplementary) European search report - dispatched on:EP17.04.2014
ClassificationIPC:A61K31/404, C07D209/88, C07D401/06, A61K31/4439, C07D471/04, A61K31/437, C07D403/12, A61K31/506, C07D209/08, A61K31/4045, A61P25/28, A61P25/18, A61P25/30, A61P25/00, A61P25/08, A61P25/14, A61P25/24
[2013/20]
CPC:
C07D209/88 (EP,US); A61K31/403 (EP,US); A61K31/404 (EP,US);
A61K31/4045 (EP,US); A61K31/4155 (EP,US); A61K31/4188 (EP,US);
A61K31/4192 (EP,US); A61K31/422 (EP,US); A61K31/437 (EP,US);
A61K31/4439 (EP,US); A61K31/506 (EP,US); A61P21/02 (EP);
A61P25/00 (EP); A61P25/02 (EP); A61P25/08 (EP);
A61P25/14 (EP); A61P25/16 (EP); A61P25/18 (EP);
A61P25/22 (EP); A61P25/24 (EP); A61P25/28 (EP);
A61P25/30 (EP); A61P25/36 (EP); A61P27/02 (EP);
A61P9/10 (EP); C07D209/08 (EP,US); C07D209/82 (EP,US);
C07D209/86 (EP,US); C07D401/06 (EP,US); C07D401/12 (EP,US);
C07D403/06 (EP,US); C07D403/12 (EP,US); C07D405/12 (EP,US);
C07D413/06 (EP,US); C07D471/04 (EP,US); C07D495/04 (EP,US);
C07F5/022 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/20]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:PRO-NEUROGENE VERBINDUNGEN[2013/20]
English:PRO-NEUROGENIC COMPOUNDS[2013/20]
French:COMPOSÉS PRONEUROGÈNES[2013/20]
Entry into regional phase24.01.2013National basic fee paid 
24.01.2013Search fee paid 
24.01.2013Designation fee(s) paid 
24.01.2013Examination fee paid 
Examination procedure24.01.2013Examination requested  [2013/20]
18.11.2014Amendment by applicant (claims and/or description)
16.03.2015Despatch of a communication from the examining division (Time limit: M06)
26.10.2015Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
05.01.2016Reply to a communication from the examining division
16.03.2016Despatch of a communication from the examining division (Time limit: M06)
23.09.2016Reply to a communication from the examining division
18.04.2017Cancellation of oral proceeding that was planned for 28.04.2017
28.04.2017Date of oral proceedings (cancelled)
17.05.2017Communication of intention to grant the patent
22.09.2017Fee for grant paid
22.09.2017Fee for publishing/printing paid
22.09.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.03.2015
Opposition(s)09.08.2018No opposition filed within time limit [2018/42]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
05.01.2016Request for further processing filed
05.01.2016Full payment received (date of receipt of payment)
Request granted
22.01.2016Decision despatched
Fees paidRenewal fee
10.07.2013Renewal fee patent year 03
14.07.2014Renewal fee patent year 04
10.07.2015Renewal fee patent year 05
11.07.2016Renewal fee patent year 06
12.07.2017Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU07.07.2011
AL08.11.2017
AT08.11.2017
CY08.11.2017
CZ08.11.2017
EE08.11.2017
ES08.11.2017
FI08.11.2017
HR08.11.2017
IT08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
MK08.11.2017
PL08.11.2017
PT08.11.2017
RO08.11.2017
RS08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
LU07.07.2018
MT07.07.2018
BE31.07.2018
[2020/33]
Former [2020/31]HU07.07.2011
AT08.11.2017
CY08.11.2017
CZ08.11.2017
EE08.11.2017
ES08.11.2017
FI08.11.2017
HR08.11.2017
IT08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
MK08.11.2017
PL08.11.2017
PT08.11.2017
RO08.11.2017
RS08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
LU07.07.2018
MT07.07.2018
BE31.07.2018
Former [2020/28]HU07.07.2011
AT08.11.2017
CY08.11.2017
CZ08.11.2017
EE08.11.2017
ES08.11.2017
FI08.11.2017
HR08.11.2017
IT08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
PL08.11.2017
PT08.11.2017
RO08.11.2017
RS08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
LU07.07.2018
MT07.07.2018
BE31.07.2018
Former [2020/27]HU07.07.2011
AT08.11.2017
CY08.11.2017
CZ08.11.2017
EE08.11.2017
ES08.11.2017
FI08.11.2017
HR08.11.2017
IT08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
PL08.11.2017
PT08.11.2017
RO08.11.2017
RS08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
LU07.07.2018
MT07.07.2018
BE31.07.2018
Former [2020/16]AT08.11.2017
CY08.11.2017
CZ08.11.2017
EE08.11.2017
ES08.11.2017
FI08.11.2017
HR08.11.2017
IT08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
LU07.07.2018
MT07.07.2018
BE31.07.2018
Former [2020/08]AT08.11.2017
CY08.11.2017
CZ08.11.2017
EE08.11.2017
ES08.11.2017
FI08.11.2017
HR08.11.2017
IT08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
LU07.07.2018
MT07.07.2018
BE31.07.2018
Former [2019/24]AT08.11.2017
CY08.11.2017
CZ08.11.2017
EE08.11.2017
ES08.11.2017
FI08.11.2017
HR08.11.2017
IT08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
LU07.07.2018
BE31.07.2018
Former [2019/17]AT08.11.2017
CY08.11.2017
CZ08.11.2017
EE08.11.2017
ES08.11.2017
FI08.11.2017
HR08.11.2017
IT08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
LU07.07.2018
Former [2019/15]AT08.11.2017
CY08.11.2017
CZ08.11.2017
EE08.11.2017
ES08.11.2017
FI08.11.2017
HR08.11.2017
IT08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/52]AT08.11.2017
CY08.11.2017
CZ08.11.2017
EE08.11.2017
ES08.11.2017
FI08.11.2017
HR08.11.2017
IT08.11.2017
LT08.11.2017
LV08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/40]AT08.11.2017
CY08.11.2017
CZ08.11.2017
EE08.11.2017
ES08.11.2017
FI08.11.2017
HR08.11.2017
IT08.11.2017
LT08.11.2017
LV08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/39]AT08.11.2017
CY08.11.2017
CZ08.11.2017
EE08.11.2017
ES08.11.2017
FI08.11.2017
HR08.11.2017
IT08.11.2017
LT08.11.2017
LV08.11.2017
PL08.11.2017
RS08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/37]AT08.11.2017
CY08.11.2017
CZ08.11.2017
EE08.11.2017
ES08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
PL08.11.2017
RS08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/24]AT08.11.2017
ES08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
RS08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/23]AT08.11.2017
ES08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
RS08.11.2017
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/22]ES08.11.2017
FI08.11.2017
LT08.11.2017
NO08.02.2018
Documents cited:Search[X]WO2009094668  (MEDIVATION TECHNOLOGIES INC [US], et al) [X] 1-15 * pages 2-4; example - *;
 [X]WO2010051503  (MEDIVATION TECHNOLOGIES INC [US], et al) [X] 1-15 * pages 2-4; example - *;
 [XP]WO2011019417  (MEDIVATION TECHNOLOGIES INC [US], et al) [XP] 1-15 * pages 2-5; example - *;
 [XP]  - ANDREW A. PIEPER ET AL, "Discovery of a Proneurogenic, Neuroprotective Chemical", CELL, (20100709), vol. 142, no. 1, doi:10.1016/j.cell.2010.06.018, ISSN 0092-8674, pages 39 - 51, XP055099451 [XP] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.cell.2010.06.018
 [X]  - MURUGANANTHAM ET AL, "Synthesis, anticonvulsant and antihypertensive activities of 8-substituted quinoline derivatives", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, (20041001), vol. 27, no. 10, doi:10.1248/BPB.27.1683, ISSN 0918-6158, pages 1683 - 1687, XP002367608 [X] 10 * compounds 3,15 *

DOI:   http://dx.doi.org/10.1248/bpb.27.1683
 [X]  - INGUVA RAVLEE ET AL, "Pharmacological Evaluation of Some New 6-Amino/Methyl Pyridine Derivatives", CHEMICAL & PHARMACEUTICAL BULLETIN, (20030101), vol. 51, no. 2, doi:10.1248/cpb.51.162, ISSN 0009-2363, pages 162 - 170, XP055113120 [X] 10 * compounds 2f,4f *

DOI:   http://dx.doi.org/10.1248/cpb.51.162
International search[Y]EP1094063  (APPLIED RESEARCH SYSTEMS [AN]);
 [Y]US6514968  (TENBRINK RUTH ELIZABETH [US]);
 [XP]WO2010081115  (UNIV TEXAS SOUTHWESTERN MED CT [US], et al);
 [Y]  - RAMAMOORTHY D., "Synthesis of small molecule inhibitors targeting signal transduction pathways", M.S. THESIS, UNIVERSITY OF SOUTH FLORIDA, (2009), pages I - IX, 1 - 164, XP055082019
 [Y]  - ENYEDY ET AL., "Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening.", J MED CHEM., (2001), vol. 44, pages 4313 - 4324, XP002192170

DOI:   http://dx.doi.org/10.1021/jm010016f
by applicantEP1094063
    - PARK ET AL., SCIENCE, (20081107), vol. 322, pages 963 - 6
    - ZHANG ET AL., J TRANSL MED., (20081105), vol. 6, no. 1, page 67
    - POESEN ET AL., J. NEUROSCI., (20081015), vol. 28, no. 42, pages 10451 - 9
    - NEGRIN ET AL., BIOMATERIALS, (2001), vol. 22, no. 6, page 563
    - ASSO, V.; GHILARDI, E.; BERTINI, S.; DIGIACOMO, M.; GRANCHI, C.; MINUTOLO, F.; RAPPOSELLI, S.; BORTOLATO, A.; MORO, S.; MACCHIA, M, CHEMMEDCHEM, (2008), vol. 3, pages 1530 - 1534
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.